Knee osteoarthritis is among the more actively researched applications of stem cell therapy, with a meaningfully more developed evidence base than many other conditions covered on this site — worth understanding both what's supported and where the real limits are.
As of 2026, neither the FDA nor INVIMA (Colombia's regulatory authority) has approved stem cell, PRP, or exosome products specifically for most orthopedic or aesthetic indications. This does not mean these treatments are unsafe or ineffective — it means they operate in a space where clinical evidence and regulatory approval haven't yet aligned. Any provider should be transparent about this distinction.
What the evidence actually shows
Clinical studies have demonstrated pain and function improvements (measured through tools like the WOMAC index) for patients with moderate osteoarthritis, alongside a generally favorable safety profile. Globally, 224 clinical trials are investigating stem cell therapies for osteoarthritis as of 2026 — a substantial and active research area, though still short of the large-scale definitive trials that would support a stronger evidence rating.
This treatment is most evidence-supported for moderate osteoarthritis (Kellgren-Lawrence grade 2–3) — not for advanced, bone-on-bone (grade 4) arthritis, where joint replacement typically remains the more appropriate intervention. A responsible provider will assess your specific imaging and stage before recommending this treatment.
What a legitimate evaluation should include
- Recent imaging to confirm your specific osteoarthritis grade
- An honest discussion of whether your specific case falls within the evidence-supported range
- Realistic expectations — symptom improvement, not cartilage regeneration to a "normal" joint
How this compares to other options
See our PRP vs. stem cell comparison for how this fits alongside other regenerative options, and discuss with your physician how it compares to more established options like corticosteroid injections or eventual surgical intervention for your specific case.
Setting realistic expectations
Improvement in pain and function scores, not disease reversal, is the realistic and evidence-supported goal for appropriately selected patients — a provider promising cartilage regrowth or a "cure" is overstating what current evidence supports.
Ready to talk to someone?
Message us on WhatsApp for a free, no-obligation consultation.